AHL Investment Management Inc. Raises Stake in Johnson & Johnson (NYSE:JNJ)

AHL Investment Management Inc. grew its position in Johnson & Johnson (NYSE:JNJ) by 29.8% in the 2nd quarter, according to its most recent disclosure with the SEC. The fund owned 22,492 shares of the company’s stock after buying an additional 5,170 shares during the period. Johnson & Johnson makes up about 2.4% of AHL Investment Management Inc.’s investment portfolio, making the stock its 13th largest holding. AHL Investment Management Inc.’s holdings in Johnson & Johnson were worth $3,287,000 at the end of the most recent reporting period.

Several other large investors have also bought and sold shares of the company. Christopher J. Hasenberg Inc purchased a new stake in Johnson & Johnson during the first quarter valued at $31,000. Keener Financial Planning LLC bought a new position in shares of Johnson & Johnson in the fourth quarter worth about $40,000. WFA Asset Management Corp grew its holdings in shares of Johnson & Johnson by 61.4% in the fourth quarter. WFA Asset Management Corp now owns 255 shares of the company’s stock worth $40,000 after purchasing an additional 97 shares during the last quarter. Vermillion & White Wealth Management Group LLC bought a new position in shares of Johnson & Johnson in the fourth quarter worth about $44,000. Finally, Disciplined Equity Management Inc. bought a new position in Johnson & Johnson during the 4th quarter worth about $45,000. 69.55% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several equities analysts recently commented on JNJ shares. Daiwa Capital Markets lowered shares of Johnson & Johnson from an “outperform” rating to a “neutral” rating and decreased their price objective for the company from $160.00 to $150.00 in a research report on Tuesday, July 23rd. Sanford C. Bernstein raised their price objective on shares of Johnson & Johnson from $161.00 to $171.00 in a research note on Thursday, July 18th. Daiwa America cut shares of Johnson & Johnson from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, July 23rd. TD Securities dropped their price target on shares of Johnson & Johnson from $195.00 to $185.00 in a research note on Thursday, July 18th. Finally, Royal Bank of Canada reissued an “outperform” rating and issued a $175.00 price target on shares of Johnson & Johnson in a research note on Tuesday, July 30th. Seven investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. According to MarketBeat.com, Johnson & Johnson currently has an average rating of “Moderate Buy” and an average price target of $173.21.

Johnson & Johnson Price Performance

Shares of JNJ traded down $0.74 during trading hours on Monday, reaching $159.88. 7,529,117 shares of the company traded hands, compared to its average volume of 7,356,028. The company has a quick ratio of 0.85, a current ratio of 1.07 and a debt-to-equity ratio of 0.44. The stock has a market capitalization of $384.78 billion, a PE ratio of 9.94, a price-to-earnings-growth ratio of 2.63 and a beta of 0.52. Johnson & Johnson has a fifty-two week low of $143.13 and a fifty-two week high of $175.60. The stock has a fifty day simple moving average of $151.17 and a 200 day simple moving average of $153.06.

Johnson & Johnson (NYSE:JNJ) last released its earnings results on Wednesday, July 17th. The company reported $2.82 earnings per share for the quarter, topping the consensus estimate of $2.71 by $0.11. Johnson & Johnson had a return on equity of 36.60% and a net margin of 46.34%. The firm had revenue of $22.45 billion for the quarter, compared to the consensus estimate of $22.33 billion. During the same period in the prior year, the business posted $2.80 earnings per share. The firm’s revenue for the quarter was up 4.3% compared to the same quarter last year. As a group, research analysts predict that Johnson & Johnson will post 10.07 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 10th. Investors of record on Tuesday, August 27th will be given a dividend of $1.24 per share. This represents a $4.96 annualized dividend and a yield of 3.10%. The ex-dividend date of this dividend is Tuesday, August 27th. Johnson & Johnson’s dividend payout ratio (DPR) is presently 30.92%.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.